Pacira BioSciences, Inc. PCRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $177.38M+5.0% | $196.87M+5.1% | $179.52M+6.5% | $181.1M+1.7% | $168.92M+1.1% | ||
| $36.41M+6.1% | $40.3M+1.0% | $34.28M-11.8% | $40.87M-7.7% | $34.31M-27.6% | ||
| $140.96M+4.7% | $156.57M+6.2% | $145.24M+12.0% | $140.23M+4.8% | $134.62M+12.5% | ||
| 79.5%-0.2pp | 79.5%+0.8pp | 80.9%+4.0pp | 77.4%+2.3pp | 79.7%+8.1pp | ||
| $28.07M+10.8% | $37.45M+56.7% | $25.97M+35.9% | $28.2M+38.7% | $25.34M+39.0% | ||
| $93.94M+8.3% | $101.61M+27.6% | $91.8M+23.5% | $88.58M+30.0% | $86.78M+20.5% | ||
| $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | ||
| $2.28M+137% | —— | —— | —— | -$6.19M— | ||
| $170.47M+2.1% | $194.53M+19.7% | $173.15M-43.8% | $172.6M+15.2% | $166.93M+8.5% | ||
| $6.9M+247% | $2.34M— | $6.36M+105% | $8.5M-69.9% | $1.99M-84.9% | ||
| 3.9%+2.7pp | 1.2%— | 3.5%+86.3pp | 4.7%-11.2pp | 1.2%-6.7pp | ||
| $3.7M-19.2% | $3.89M-16.8% | $4.28M-8.7% | $4.7M+20.9% | $4.58M+38.1% | ||
| $1.93M-72.0% | $2.3M-58.7% | $8.53M+55.7% | $5.01M+5.5% | $6.9M+76.7% | ||
| -$1.9M-128% | -$1.77M-315% | $3.16M+371% | -$10.43M-225% | $6.72M+1,469% | ||
| $5M-42.6% | $571K— | $9.52M+107% | -$1.93M-105% | $8.71M-36.2% | ||
| $2.08M-46.5% | —— | $4.09M-11.2% | $2.92M-83.5% | $3.89M-16.5% | ||
| $2.92M-39.4% | $1.64M— | $5.43M+104% | -$4.85M-126% | $4.81M-46.4% | ||
| 1.6%-1.2pp | 0.8%— | 3%+88.1pp | -2.7%-13.3pp | 2.8%-2.5pp | ||
| $0.07-30.0% | $0.04— | $0.12+104% | -$0.11-128% | $0.10-47.4% | ||
| $0.07-30.0% | $0.04— | $0.12+104% | -$0.11-127% | $0.10-47.4% | ||
| 40.9M-12.1% | 45M-2.6% | 44.5M-3.6% | 45.5M-10.1% | 46.5M-10.9% | ||
| 40.5M-12.6% | 44.6M-3.6% | 44M-4.5% | 45.5M-1.5% | 46.3M-0.5% | ||
| $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | ||
| -$135K-103% | -$172K-225% | -$110K+9.8% | -$10.74M-27,436% | $4.4M+2,868% | ||
| $2.28M+137% | —— | —— | —— | -$6.19M— | ||
| $177.38M+5.0% | $196.87M+5.1% | $179.52M+6.5% | $181.1M+1.7% | $168.92M+1.1% | ||
| $6.9M+247% | $2.34M— | $6.36M+105% | $8.5M-69.9% | $1.99M-84.9% | ||
| $28.23M+21.9% | $23.68M— | $27.55M+123% | $35.82M-24.0% | $23.16M-26.8% | ||
| $28.23M+21.9% | $23.68M— | $27.55M+123% | $35.82M-24.0% | $23.16M-26.8% | ||
| 15.9%+2.2pp | 12%— | 15.3%+86.1pp | 19.8%-6.7pp | 13.7%-5.2pp | ||
| $6.9M+247% | $2.34M— | $6.36M+105% | $8.5M-69.9% | $1.99M-84.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacira BioSciences, Inc.'s revenue?
- Pacira BioSciences, Inc. (PCRX) generated $734.9M in revenue over the trailing twelve months, up 4.6% year over year.
- Is Pacira BioSciences, Inc. profitable?
- Pacira BioSciences, Inc. reported $5.1M in net income over the trailing twelve months, a 0.7% net margin.
- What are Pacira BioSciences, Inc.'s profit margins?
- Gross margin is 79.3% and operating margin is 3.3%, with a 0.7% net margin.
- What is Pacira BioSciences, Inc.'s earnings per share?
- Pacira BioSciences, Inc.'s diluted EPS over the trailing twelve months is $0.12.
- Where does Pacira BioSciences, Inc.'s income statement data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
